Promising Ulcerative Colitis Therapies in the various stages of development include ABX464, Etrasimod, adalimumab, tralokinumab, IV MK-7240, BBT-401-1S, Filgotinib, and others.

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) ...

For the preclinical study, colitis was induced in mice using 4% dextran sulfate sodium (DSS) in drinking water. Mice were treated with PALI-2108 at 20, 40, or 80 mg/kg BID, cyclosporine A (40 mg ...

Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug obefazimod.

Shares of Abivax (NASDAQ:ABVX) rose over 400% in Paris on Wednesday after the French biotech announced that its lead asset, ...